Capricor Therapeutics, Inc. To Present ALLSTAR Phase I Trial Data At American College of Cardiology Annual Meeting 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES, March 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63rd Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán’s presentation will highlight positive data demonstrating that the Phase I portion of the Company’s ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC